This article is more than 5 years old. Information may no longer be current.

Nicox, Novaliq to collaborate on PDE5 inhibitors for glaucoma

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Nicox has entered into a collaboration agreement with Novaliq to develop topical nitric oxide-donating phosphodiesterase-5 inhibitors and soluble guanylate cyclase stimulators, the company announced in a release.

The collaboration agreement will allow the companies to develop a novel topical ophthalmic formulation of Nicox’s NO-donating PDE5 inhibitors based on the water-free enabling EyeSol technology from Novaliq in order to lower IOP, according to the release.

“We have been impressed by Novaliq’s ability to successfully combine existing molecules and new chemical entities with their EyeSol technology,” Nicox Chairman and CEO Michele Garufi said. “It uses a novel class of excipient that offers an opportunity to create unique formulations for the development of our NO-donating PDE5 inhibitor.... These novel formulations could potentially have multiple benefits, including improved ocular comfort and enhanced drug delivery performance with no antimicrobial preservative.”